Continued investment in research and development
First written in FY2019. . Latest entry: FY2026.
- FY2026Full-year R&D expenses increased from ¥874 million to ¥904 millionAnnual report
「As a result, R&D expenses for the consolidated fiscal year amounted to ¥904 million.」
R&D expenses amounted to ¥904 million, up from ¥874 million in the previous fiscal year. - FY2026-H1Interim R&D expenses increased from ¥412 million to ¥443 millionAnnual report
「Group-wide R&D expenses for the consolidated interim period amounted to ¥443 million.」
Interim R&D expenses amounted to ¥443 million, up from ¥412 million in the same period of the previous year. It stated that there were no material changes in its R&D activities. - FY2025Full-year R&D expenses increased from ¥862 million to ¥874 millionAnnual report
「As a result, R&D expenses for the consolidated fiscal year amounted to ¥874 million.」
R&D expenses amounted to ¥874 million, up from ¥862 million in the previous fiscal year. - FY2025-H1Interim R&D expenses increased from ¥389 million to ¥412 millionAnnual report
「Group-wide R&D expenses for the consolidated interim period amounted to ¥412 million.」
Interim R&D expenses amounted to ¥412 million, up from ¥389 million in the same period of the previous year. It stated that there were no material changes in its R&D activities. - FY2024Full-year R&D expenses increased from ¥814 million to ¥862 millionAnnual report
「As a result, R&D expenses for the consolidated fiscal year amounted to ¥862 million.」
¥862 million was invested annually in R&D on resource recycling, reducing environmental impact, medical devices, EHV, composite materials, analytical technologies, 3D printers and other areas, up from ¥814 million in the previous fiscal year. - FY2024-Q2First-half R&D expenses: ¥389 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative second quarter amounted to ¥389 million. There were no material changes in the Group's R&D activities during the consolidated cumulative second quarter.」
The Group recorded ¥389 million in R&D expenses on a first-half cumulative basis. Although this was down from ¥429 million in the same period of the previous year, it stated that there were no material changes in its R&D activities. - FY2024-Q1First-quarter R&D expenses: ¥188 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative first quarter amounted to ¥188 million.」
The Group recorded ¥188 million in R&D expenses in the first quarter. It stated that there were no material changes in its R&D activities. - FY2023Full-year R&D expenses: ¥814 millionAnnual report
「As a result, R&D expenses for the consolidated fiscal year amounted to ¥814 million.」
¥814 million was invested annually in R&D on high-value-added products, reducing environmental impact, medical devices, EHV, composite materials, analytical technologies, 3D printers and other areas. - FY2023-Q3Cumulative third-quarter R&D expenses: ¥613 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative third quarter amounted to ¥613 million. There were no material changes in the Group's R&D activities during the consolidated cumulative third quarter.」
Cumulative third-quarter R&D expenses amounted to ¥613 million, and it stated that there were no material changes in its R&D activities. - FY2023-Q2First-half R&D expenses: ¥429 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative second quarter amounted to ¥429 million. There were no material changes in the Group's R&D activities during the consolidated cumulative second quarter.」
The Group recorded ¥429 million in R&D expenses on a first-half cumulative basis and stated that there were no material changes in its R&D activities. - FY2023-Q1First-quarter R&D expenses: ¥212 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative first quarter amounted to ¥212 million.」
The Group recorded ¥212 million in R&D expenses in the first quarter. It stated that there were no material changes in its R&D activities. - FY2022-Q3Cumulative third-quarter R&D expenses: ¥506 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative third quarter amounted to ¥506 million. There were no material changes in the Group's R&D activities during the consolidated cumulative third quarter.」
Cumulative third-quarter R&D expenses amounted to ¥506 million, up from ¥470 million in the same period of the previous year. It stated that there were no material changes in its R&D activities. - FY2022-Q2First-half R&D expenses: ¥331 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative second quarter amounted to ¥331 million. There were no material changes in the Group's R&D activities during the consolidated cumulative second quarter.」
The Group recorded ¥331 million in R&D expenses on a first-half cumulative basis and stated that there were no material changes in its R&D activities. - FY2022-Q1First-quarter R&D expenses: ¥168 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative first quarter amounted to ¥168 million.」
The Group recorded ¥168 million in R&D expenses in the first quarter. It stated that there were no material changes in its R&D activities. - FY2021-Q3Third-quarter R&D expenses: ¥482 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative third quarter amounted to ¥482 million. There were no material changes in the Group's R&D activities during the consolidated cumulative third quarter.」
Cumulative third-quarter R&D expenses amounted to ¥482 million. It stated that there were no material changes in its R&D activities. - FY2021-Q2First-half R&D expenses: ¥320 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative second quarter amounted to ¥320 million. There were no material changes in the Group's R&D activities during the consolidated cumulative second quarter.」
First-half cumulative R&D expenses amounted to ¥320 million, and it stated that there were no material changes in its R&D activities. - FY2021-Q1First-quarter R&D expenses: ¥154 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative first quarter amounted to ¥154 million.」
The Group recorded ¥154 million in R&D expenses in the first quarter. It stated that there were no material changes in its R&D activities. - FY2020Full-year R&D expenses: ¥611 millionAnnual report
「As a result, R&D expenses for the consolidated fiscal year amounted to ¥611 million.」
¥611 million was invested annually in R&D on high-value-added products, reducing environmental impact, medical devices, EHV, composite materials, analytical technologies, 3D printers and other areas. - FY2020-Q3Third-quarter R&D expenses: ¥470 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative third quarter amounted to ¥470 million. There were no material changes in the Group's R&D activities during the consolidated cumulative third quarter.」
The Group recorded ¥470 million in R&D expenses on a cumulative third-quarter basis. It stated that there were no material changes in its R&D activities. - FY2020-Q2First-half R&D expenses: ¥300 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative first half amounted to ¥300 million.」
The Group recorded ¥300 million in R&D expenses on a first-half cumulative basis. It stated that there were no material changes in its R&D activities. - FY2020-Q1First-quarter R&D expenses: ¥151 millionAnnual report
「Group-wide R&D expenses for the consolidated cumulative first quarter amounted to ¥151 million.」
The Group recorded ¥151 million in R&D expenses in the first quarter. - FY2019First statedAnnual report
「As a result, R&D expenses for the consolidated fiscal year amounted to ¥536 million.」
¥536 million was invested annually in R&D on high-value-added products, reducing environmental impact, medical devices, EHV, composite materials, analytical technologies, 3D printers and other areas.